Kornimate/medical-research-clean huggingface dataset:
efficacy and safety of conbercept in macular edema secondary to retinal vein occlusion

Conditions: Retinal Vein Occlusion

Summary: this is a phase ii, single arm, open label clinical trial. 60 rvo patients (including 30 brvo and 30 crvo, respectively) are enrolled in the study. the study included a fixed treatment period (3 months) and a prn period (6 months). in the fixed treatment period patients will receive 3 consecutive monthly intravitreal of 0.5 mg conbercept. in the prn period, patients are monthly visited and retreatment will be needed according to the retreatment criteria pre-specified.


Eligibility criteria:
inclusion criteria: 1. ability and willingness to provide signed informed consent form. 2. age ≥ 18, both male and female。 3. ocular inclusion criterion (study eye): * diagnosis of foveal center-involved macular edema due to rvo (both crvo and brvo) within 6 months. * best corrected visual acuity (bcva) letter score in the study eye of ≤ 73（snellen equivalents 20/40）. * central retinal thickness by oct in the study eye ≥ 320 μm. exclusion criteria: 1. brisk afferent pupillary defect. 2. history of any anti-vegf treatment in the study and/or system within 6 months before enrollment, and/or in the fellow eye within 3 month. 3. history of intraocular and/or peri-ocular corticosteroid use in the study eye within 3 months, and/or history of use steroids systemic (p.o., i.m., i.v.) within 1 month. 4. any active infection involving the ocular including blepharitis, infectious conjunctivitis, keratitis, scleritis, endophthalmitis in either eye. 5. any inflammatory cells detected in the anterior chamber and/or vitreous in the study eye. 6. presence of non-rvo disease, in the opinion of the investigator, might cause macular edema, such as amd (wet or dry), diabetes retinopathy, uveitis etc. 7. neovascular change in the study eye and/or neovascularization of the iris or neovascular glaucoma in study eye at baseline. 8. patients with substantial cataract that, in the opinion of the investigator, is likely to be decreasing visual acuity by equal or more than 3 lines or medicine or surgery treatment are needed in the study eye within 4 months. 9. patients diagnosed with systemic immune diseases and any uncontrolled clinical disease. 10. pregnant or nursing women. 11. patients need to exclude in the opinion of investigator.
campus expanded "classification and assessment of mental health performance using semantics expanded"

Conditions: Suicide; Suicidal; Suicide, Attempted; Suicidal Ideation; Depression; Anxiety; Aggression; Trauma, Psychological

Summary: open enrollment study to collect data for the optimization of machine learning models for use in an app for the early detection of mental health and suicidal risk.


Eligibility criteria:
inclusion criteria: * currently a client receiving services from a mhp at a school or outpatient setting, or at a college/university counseling center * age ≥ 8 years old * able to provide informed consent, parental permission or assent * english as a primary language exclusion criteria: * participants with communication disorders (linguistic or articulation) * any minor participants for whom parental or legal guardian consent cannot be obtained. * any adult participant for whom legal authorized representative (lar) consent cannot be obtained. * history of any other serious medical or psychiatric condition that would interfere with the ability of the patient to complete the study or would make it ethically unfeasible to enroll them * participants with an intellectual and / or neurocognitive disability that the mhp deems a barrier to participation * any participant, who at the discretion of the mhp, should not be enrolled
feasibility of using the livongo-insulia study app for patients with type 2 diabetes [pilot study]

Conditions: Type 2 Diabetes Treated With Insulin

Summary: the livongo-insulia study app pilot study (lisa pilot) is a 3-month, prospective, interventional study. the purpose of this pilot study is to evaluate the feasibility of using the livongo-insulia study app for individuals with type 2 diabetes using basal insulin. this will be assessed by measuring the impact of the livongo-insulia study app on glycemic control for these individuals.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * lives in the u.s. * able to speak, read and write in english * diagnosed with type 2 diabetes * currently treated with long-acting basal insulin analog (lantus, levemir, toujeo, basaglar, tresiba u-100) and taking 1 injection per day * takes a daily dose ≤ 0.75 units/kg * estimated a1c ≥ 8% (based on existing livongo data) * has been enrolled in livongo for at least 12 weeks * uses an iphone compatible with insulia's compatibility matrix (iphone 5 or higher; ios 8 or newer) * willing to complete study questionnaires * willing to complete at-home a1c kits * willing to check before breakfast blood glucose at least once per day exclusion criteria: * diagnosis of type 1 diabetes * currently using a long-acting basal insulin analog that is not supported by insulia * currently using rapid-acting, short-acting, or intermediate-acting or premixed insulins * currently pregnant or planning pregnancy
neuro-modulation of the depressed brain using working memory training and transcranial direct current stimulation (tdcs)

Conditions: Depression

Summary: the goal of this project is to train currently major depressed patients on fundamental aspects of working memory while the investigators administer transcranial direct current stimulation (tdcs) over the left dorsolateral prefrontal cortex (dlpfc) during these training sessions. this working memory training would be performed using adaptive paced auditory serial addition tasks (pasat). the effects after two weeks of working memory training combined with tdcs or sham placebo (10 sessions) will be measured on different variables, each measured at the start and at the end of the two weeks of training. the investigators expect the greatest anti depressant results and cognitive enhancements in the group of depressed patients that received tdcs combined with working memory training.


Eligibility criteria:
inclusion criteria: * depressive disorder, major (scid) * hdrs-24 \> 21 exclusion criteria: -other axis i disorders, including bipolar disorder, schizophrenia, substance abuse disorders. any axis ii disorders. * any serious/life-threatening axis iii disorders, such as congestive heart failure, pulmonary obstructive chronic disease, active neoplasia. * neurological diseases such as stroke (and post-stroke depression), dementias and others.

Keywords: anti-depressant effects
prophylactic tricuspid valve annuloplasty in patients undergoing mitral valve surgery

Conditions: Tricuspid Valve Insufficiency

Summary: de novo or progressive tricuspid regurgitation (tr) is not uncommonly observed following mitral valve surgery and associated with worse outcome. hence, concomitant tricuspid valve annuloplasty (tvp) has been recommended for patients undergoing mitral valve surgery when tricuspid annular dilatation is present even in absence of significant tr. however, whether such a strategy of "prophylactic tvp" results in improved outcomes has not been shown to date by a prospective randomized study. the investigators goal is therefore to initiate such a study and evaluate the effect of concomitant tvp on mid- and long-term outcome in patients scheduled for mitral valve surgery and tricuspid annular dilatation but \<2+ tr.


Eligibility criteria:
inclusion criteria: * scheduled for mitral valve surgery * tricuspid annular diameter \> 40mm or \>21mm/m² exclusion criteria: * tricuspid regurgitation more than 2+ * unable to provide informed consent

Keywords: tricuspid valve insufficiency cardiac valve annuloplasty outcome assessment (health care)
studio delle manifestazioni cardiovascolari a lungo termine mediante tecniche di imaging

Conditions: Cardiac Complication; COVID-19 Pneumonia

Summary: the aim of the project is to identify the prevalence and characteristics of long-term cardiovascular changes in covid-19 infection.

in the follow-up of patients with covid-19 infection, persistence of cardiovascular symptoms is common. studies of the acute phase of covid-19 infection have shown a significant prevalence of acute myocardial damage (15-44%), and imaging studies have confirmed the presence of structural changes in the pericardium and myocardium several months after the acute phase. the aim of the project is to identify the prevalence and characteristics of long-term cardiovascular changes in covid-19 infection. the study is a continuation of the project "registry "cardicovrisk"" which collected data on cardiovascular changes during the acute phase and shortly after the acute phase. the study design is retrospective observational. the study plans to enroll 240 patients hospitalized during the acute phase of covid-19 infection. patients will be collected at three separate centers. enrolled patients will undergo a baseline evaluation by history, physical examination, laboratory tests, ecg, 6-minute walking test and echocardiogram. if alterations in left ventricular or right ventricular systolic function are found, as per the standard clinical approach, a cardiac mri examination will be evaluated. identification of patients with cardiac changes is of paramount importance as they may benefit from early initiation of cardioprotective therapy and may need different follow-up strategies.

Eligibility criteria:
inclusion criteria: * patient with previous hospitalization for covid-19 infection confirmed by pharyngeal molecular swab * adult patients between 18 and 90 years of age * signature of informed consent exclusion criteria: * patient with poor echocardiographic acoustic window impairing the performance of the examination * patients with atrial fibrillation * patients with ischemic or nonischemic heart disease with known decreased left ventricular systolic function
a study of treatment patterns and clinical outcomes of psoriasis in japan

Conditions: Psoriasis

Summary: the purpose of this study is to understand current real-world treatment patterns and clinical outcomes, reasons for switching treatment, and participant characteristics using each systemic psoriasis treatment in japan.


Eligibility criteria:
inclusion criteria: * diagnosis of psoriasis * can be followed for at least 2 years * treated with any of the following systemic therapy for psoriasis at time of follow-up start: tumor necrosis factor (tnf) inhibitors (infliximab, adalimumab, and certolizumab pegol), interleukin (il)-12/23 inhibitors (ustekinumab), il-23 inhibitors(guselkumab, risankizumab, and tildrakizumab), il-17 inhibitors (secukinumab, ixekizumab, and brodalumab), apremilast, methotrexate, cyclosporine, etretinate exclusion criteria: * enrolled in any clinical trials for psoriasis in their follow-up period * developed psoriatic arthritis, guttate psoriasis, erythrodermic psoriasis, and pustular psoriasis at time of start date * treated with any of the following systemic therapy before they were diagnosed with psoriasis: tnf inhibitors (infliximab, adalimumab, and certolizumab pegol), il-12/23 inhibitors (ustekinumab), il-23 inhibitors(guselkumab, risankizumab, and tildrakizumab), il-17 inhibitors (secukinumab, ixekizumab, and brodalumab), apremilast, methotrexate, cyclosporine, etretinate

Keywords: japan observational psoriasis retrospective
research of diagnostic value for bmj infants

Conditions: Jaundice, Neonatal

Summary: breast milk jaundice (bmj) is the main cause of neonatal hyperbilirubinemia. excessive serum unconjugated bilirubin level will not only cause the interruption or early termination of breastfeeding, but also cause kernicterus. which can cause long-term dysfunction in infants. but for a long time, bmj diagnosis has relied on clinical exclusive methods, lack of objective and reliable laboratory indicators. which leads to misdiag. this project is a single-center, prospective nested case-control study. it is planned to establish a neonatal bmj cohort. according to the admission criteria, 100 cases of early-onset bmj and late-onset bmj will be completed, and 100 healthy controls collected during the same period. , compare the detection results of fecal mirna and intestinal flora of the two groups of bmj children and healthy controls, draw the roc curve of the joint diagnosis, conduct research on the combined diagnostic value of fecal mirna and intestinal flora analysis, and try to find the feasibility and practical value of diagnostic markers for feces in infants with bmj.

this project is a single-center, prospective nested case-control study to investigate feasibility and practical value of diagnostic markers in infants with bmj. according to the admission criteria, 100 cases of early-onset bmj, 100 late-onset bmj and 100 healthy controls will be selected. their feces, peripheral venous blood and mothers' breast milk were collected for further testing. compare the detection results of fecal mirna and intestinal flora of the two groups of bmj children and healthy controls, draw the roc curve of the joint diagnosis, conduct research on the combined diagnostic value of fecal mirna and intestinal flora analysis. this study is to find the objective and reliable laboratory indicators to diagnose bmj.

Eligibility criteria:
inclusion criteria: * all the following conditions must be met 1. term newborns admitted to hospital with "neonatal hyperbilirubinemia" 2. exclusive breastfeeding or mainly breastfeeding 3. exclude perinatal infection, g-6p-d deficiency, homoimmune hemolysis, polycythemia, scalp hematoma, intracranial hemorrhage, cholestasis, hypoglycemia, hypothyroidism, hypothermia, neonatal asphyxia, fetus pathological jaundice factors such as delayed stool excretion. exclusion criteria: * as long as any one of the following conditions should be excluded 1. during the follow-up period, breastfeeding was terminated or the daily milk powder intake exceeded 200 ml. 2. other pathological jaundice was diagnosed during the follow-up period. 3. take probiotics during the sampling period. 4. the guardian asked to withdraw from the study halfway.
modified surface of plga nanoparticles in smart hydrogel

Conditions: Antibiotic Resistant Infection

Summary: nanoparticles containing antibiotic were prepared and incorporated in in situ gel to treat recurrent endodontic infections

enterococcus faecalis is the main cause of endodontic infections and form biofilm on dentin, resulting in treatment-resistant periradicular lesions. to overcome these problems, antibacterial nanoparticles were used because of their small size, sustained release and positive charge which interact with the negatively charged surface of bacterial cell causing its destruction. in this light, ciprofloxacin hydrochloride (cip) in chitosan coated plga nanoparticles (cip-cs-plga-nps) and free cip were embedded in pluronic® 407/188 to form thermosensitive gels(f1) and (f2) respectively, that were investigated in terms of viscosity, gelation temperature and in-vitro release. the antibacterial efficacy of f1 and f2 were clinically investigated on patients then compared to cip and ca(oh)2 pastes by determining bacterial reduction percent and biofilm inhibition assay

Eligibility criteria:
inclusion criteria: * root canal filled single rooted teeth with post treatment disease manifested by one or more of the following signs and symptoms: * history of recurrent acute and/or chronic periapical abscess * pain on palpation and/or percussion at least after one month of previous procedure * radiographic evidence of bone loss either as a new developing lesion or an increase in the size of a pre-existing one. exclusion criteria: * teeth that were badly broken down indicated for extraction or with difficult isolation * immuno-compromised patients. * patients with history of taking antibiotics orally. * periodontally affected teeth.

Keywords: nanoparticles endodontics infection
identifying genes that may increase the risk for heart disease in african americans

Conditions: Heart Diseases

Summary: heart disease and stroke disproportionately affect african americans in the united states. these conditions are likely caused by both environmental and genetic factors. this study will attempt to identify specific genes of african and european ancestral origins that may influence the development of heart disease in african americans.

african americans have a high risk of developing heart disease and stroke, and are more likely to die from heart-related illnesses than other racial and ethnic groups. a large majority of african americans are descendants of both african and european ancestors who mixed five to six generations ago. because only a few generations have passed since that time, it is still possible to identify specific genes, the basic units of heredity, as being either african or european in origin. this is a sub study of the jackson heart study, which is examining the environmental and genetic factors that influence the development of heart disease in african americans. in this study, researchers will examine genes from participants in the jackson heart study to identify specific african and european genes that influence the development of heart disease in african american men and women. this study will use genetic samples from individuals participating in the jackson heart study. there will be no study visits for participants. study researchers will examine the genetic samples and identify specific african and european genes that may influence the development of heart disease, high blood pressure, lipid disorders, left ventricular hypertrophy, and low birth weight.

Eligibility criteria:
inclusion criteria: * unrelated african americans living in hinds, rankin, or madison county, mississippi enrolled in the jackson heart study

Keywords: blood pressure, high stroke hypertension diabetes mellitus obesity cerebrovascular accident atherosclerosis
safety and efficacy of natalizumab in combination with remicade in the treatment of crohn's disease

Conditions: Crohn's Disease

Summary: the purpose of this study is to determine the safety, tolerability, and efficacy of natalizumab in individuals diagnosed with active crohn's disease that are not in remission (cdai greater than/equal to 150) and are currently taking remicade. it is thought that natalizumab may stop the movement of certain cells, known as white blood cells, into bowel tissue. these cells are thought to cause damage in the bowel leading to the symptoms of crohn's disease. patients who complete this study may be eligible for long-term natalizumab therapy via extension protocol eln100226-351.


Eligibility criteria:
* male and female patients at least 18 years of age with at least a six-month history of crohn's disease and who are currently receiving remicade and are not in remission (cdai greater than/equal to 150) * women must not be breastfeeding or pregnant, and must not become pregnant during the study.
ct change management in trauma patients

Conditions: Trauma; Neurologic Deficits

Summary: in high-volume trauma centers, multi-slice ct scanners have become the routine imaging modality for screening trauma patients due to their speed and accuracy. in trauma patients with no known neurologic deficits, diagnostic ct is often obtained though it remains unclear whether this affects management of the patient \[1\]. with the growing cost of health care, a careful look at the benefit and cost of ct is needed to determine how to best utilize this modality in the evaluation of trauma patients. hypothesis: in trauma patients with absence of neurologic defects, the addition of comprehensive ct does not change overall clinical management.

objectives: the primary objective of this study is to determine the benefit of the ct scan in the clinical management or outcomes of the trauma patients with no neurologic deficits. primary outcome: percentage of trauma patients with no known neurologic deficits who underwent a ct, any clinically impactful ct findings. secondary outcome: percentage of benefits ct provides in clinical features, clinical outcomes, injury severity score, gcs, age, sex, ethnicity, cause of injury, mechanism of injury, hospital length of stay, operative vs. non-operative, discharge disposition, radilogy, pathology results and images, any additional morbidities, total cost, 30-day readmission rate, and morality. and when operation does occur, the types of operation and the resulting cost and length of stay.

Eligibility criteria:
inclusion criteria: * age ≥ 18-years-old * no localizing neurologic defect * any cause or mechanism of injury * comprehensive ct obtained exclusion criteria: • any patients that are pregnant or breastfeeding
determinants of medical and surgical treatment outcomes in chronic sinusitis

Conditions: Chronic Rhinosinusitis

Summary: this research study will be completed by enrolling a prospective, observational cohort study to evaluate medical versus surgical treatment outcomes for chronic sinus disease. this investigation will compare quality of life outcomes between each treatment type, as well as measure cellular and molecular markers of inflammation in the sinus mucosa, to create models that predict improvement in quality of life following treatment.


Eligibility criteria:
inclusion criteria: * adult (\>= 18 years) * chronic rhinosinusitis as defined by the 2007 multi-disciplinary adult sinusitis guidelines * able to complete all surveys/questionnaires in english * persistent symptoms following initial medical management * received at least 1 course of broad spectrum antibiotics or culture directed antibiotics for at least a total of 14 days * received at least a 3 week trial of topical steroid sprays or at least a 5 day trial of systemic corticosteroid therapy. * counseled for subsequent treatment options including either medical management or endoscopic sinus surgery exclusion criteria: * children (\<18 years) * unable to complete all surveys/questionnaires at baseline
preloop trial: synthetic versus biological mesh for prevention of incisional hernia after loop-ileostomy closure

Conditions: Rectum Cancer

Summary: this study compares a synthetic mesh and biological implant in prevention of incisional hernia after loop-ileostomy closure.

incisional hernia after loop-ileostomy closure may be an underestimated problem. research on both biological and synthetic mesh in this context is scarce and no randomized controlled trials comparing meshes exist. the aim of this study is to compare parietene macro and permacol in prevention of incisional site hernia after temporary loop-ileostomy reversal after anterior resection and tme for rectal cancer.

Eligibility criteria:
inclusion criteria: * anterior resection and tme with temporary loop-ileostomy for rectal carcinoma * 18 years or older * patient has a life expectancy of at least 12 months. * patient signs the informed consent and agrees to attend all study visits exclusion criteria: * patient with a comorbid illness or condition that would precluded the use of surgery (asa 4-5). * patients with concurrent or previous malignant tumors within 5 years before study enrollment * patients with t4b tumors which imposed a multi-organ resection * patient undergone emergency procedures * primary rectal surgery along with major concomitant procedures (e.g. hepatectomies, other intestinal resections). * metastatic disease with life expectancy of less than 12 months * pregnancy or suspected pregnancy

Keywords: loop-ileostomy reversal hernia prevention